Chemotherapy-induced neutropenia is not only a major risk factor for infection-related
morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment …

Rituximab is the first antibody-based therapy approved in cancer. The role of this treatment
for non-Hodgkin's lymphoma has evolved significantly since its introduction. We aimed to …

Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of
distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and …

Non-Hodgkin's Lymphomas in: Journal of the National Comprehensive Cancer Network
Volume 9 Issue 5 (2011) Jump to Content User Account Sign In to save searches and organize …

Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-
Hodgkin lymphoma. It is a heterogeneous disease, and a distinctive subgroup of patients …

Hematologic toxicities of cancer chemotherapy are common and often limit the ability to
provide treatment in a timely and dose-intensive manner. These limitations may be of utmost …

Optimal dose and timing of CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy for aggressive non-Hodgkin lymphoma (NHL) is still an …

The introduction of the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
regimen 30 years ago was the great breakthrough in the treatment of advanced-stage …

Purpose: Until now molecular biologic techniques have not been easily used in daily clinical
practice to stratify patients for therapeutic purposes. Therefore, we have investigated the …

The CHOP (cyclophosphamide/doxorucibin/vincristine/prednisone) regimen has been
established as the standard treatment for diffuse large B-cell lymphoma (DLBCL). With the …